Drugs Made In America Acquisition II Corp. filed a Form 12b-25 to notify the SEC that its Quarterly Report on Form 10-Q for the period ended September 30, 2025 will be filed late. The company explains that its financial statements could not be completed in time to obtain the required review and signatures before the normal deadline. By using this notification, it indicates that it expects to file the delayed 10-Q within the short extension period permitted under SEC Rule 12b-25.
Drugs Made In America Acquisition II Corp. reported an insider transaction on a Form 4. Director Catherine Do acquired 100,000 ordinary shares on 09/26/2025 under transaction code J.
According to the footnote, the shares were acquired from the Issuer’s sponsor, Drugs Made In America Acquisition II LLC, for no consideration. Following the transaction, the reporting person beneficially owned 100,000 shares held in direct ownership.